Pfizer Inc. Earnings: Can the Big Pharma Stock Keep Recovering?

Pfizer has climbed on hopes that its reorganization will make it more profitable, but can it beat out its competitors? Find out here.

Jan 25, 2014 at 5:26PM

Pfizer (NYSE:PFE) will release its quarterly report on Tuesday, and it has seen its stock perform extremely well over the past quarter, hitting levels not seen in almost a decade. Yet even as competition against Merck (NYSE:MRK), AbbVie (NYSE:ABBV), and other big pharmaceutical companies starts to heat up, Pfizer is contemplating some big strategic moves that could change the way it does business in the future.

Like many of its peers, Pfizer has had to deal with an extreme patent cliff in recent years. That has forced the company to look in new directions to develop potential replacements for blockbuster drugs that have lost patent protection. Fortunately, Pfizer has had considerable success in those efforts, but investors still question whether they'll be enough to hold Merck, AbbVie, and dozens of other competitors at bay. Let's take an early look at what's been happening with Pfizer over the past quarter and what we're likely to see in its report.

G
Source: Wikimedia Commons.

Stats on Pfizer

Analyst EPS Estimate

$0.52

Change From Year-Ago EPS

10.6%

Revenue Estimate

$13.35 billion

Change From Year-Ago Revenue

(11.4%)

Earnings Beats in Past 4 Quarters

3

Source: Yahoo! Finance.

What's next for Pfizer earnings?
In recent months, analysts have gotten a little less certain about Pfizer earnings, cutting fourth-quarter estimates by a penny per share and full-year 2014 projections by $0.03 per share. The stock has come off its highs and has been essentially flat since late October.

Pfizer's third-quarter earnings report shows the extent to which the pharma giant has gone to support its profitability despite key patent-cliff revenue losses. Extensive cost-cutting paid off with a modest earnings beat, and even though sales of off-patent Lipitor fell substantially, patent-protected drugs like Lyrica and Celebrex posted solid gains. More encouragingly, cancer-drug sales jumped 24%, with lung-cancer treatment Xalkori seeing sales almost double and kidney-cancer drug Inlyta almost tripling its sales. Yet even with those results, Pfizer cut its guidance for the full year.

One problem that Pfizer has had lately is that new drugs have had slower launches than the company had hoped. For instance, with rheumatoid arthritis drug Xeljanz, Pfizer faces competition from AbbVie's Humira, even though Humira is injected while patients take Xeljanz in pill form. Similar issues have plagued its more recent Eliquis launch from late 2012.

Patent-cliff issues will also still face Pfizer in the future. Last month, the company settled a dispute with Teva Pharmaceutical (NYSE:TEVA) by allowing the generic drugmaker to make a version of its key Viagra drug beginning in late 2017. The agreement will pay Pfizer an undisclosed amount for the rights, but it could also end up hurting Pfizer's branded Viagra sales when the Teva version becomes available almost two and a half years before Viagra's 2020 expiration of U.S. patent exclusivity.

One issue investors are following is whether Pfizer will take further steps to restructure its business. With plans to split up its commercial operations to separate generics from branded drugs, some believe that Pfizer will eventually spin off or sell its generics unit to focus on proprietary drug development. That would be consistent both with its own past trend as well as those of many of its peers, with Johnson & Johnson (NYSE:JNJ) being the obvious example as it considers the sale of its Ortho diagnostics unit to focus more on pharmaceuticals.

In the Pfizer earnings report, watch to see whether the drugmaker is able to boost sales growth of its key drug offerings. Moreover, if the company releases details about its future corporate strategy, it could make investors feel more comfortable about where the stock is headed both in the near future and for years to come.

Get smart about health-care stocks
The best way to play the pharma and biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Click here to add Pfizer to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool recommends Johnson & Johnson and Teva Pharmaceutical Industries and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers